Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)Blue Cross Blue Shield RI Balloon Dilation Policy …
    Ask Trek AI about this page
    DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Balloon Dilation of the Eustachian Tube

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This draft policy governs medical necessity, prior authorization, coverage, and coding for balloon dilation of the eustachian tube (BDET) for Medicare Advantage and Commercial members, including adult and pediatric criteria.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyBalloon Dilation of the Eustachian Tube (BDET) — Clinical/Medical Policy (Draft)
    Policy CodePolicy N/A
    Change TypeMaterial updates: pediatric indication addedadult criteria clarifiedCPT codes operationalized
    Effective DateSep 1, 2026
    Last ReviewMay 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for Medicare Advantage members and document comprehensive diagnostic assessment and a 4–6 week trial of intranasal corticosteroid therapy when indicated before BDET.
    SourceLink
    POLICY UPDATE CHANGES

    Pediatric indication (ages 8-17) stated as medically necessary when specific criteria are met following FDA expansion and supporting evidence.

    Detailed explicit medical necessity criteria for adults including duration of symptoms (>=3 months), required diagnostic testing, failure of medical management, exclusion of other causes, reversibility testing, and contraindications.

    CPT codes 69705 and 69706 designated medically necessary for Medicare Advantage Plans and Commercial Products when medical criteria are met.

    Statement that evidence is sufficient to determine the technology results in an improvement in the net health outcome.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2CPT codes listed as medically necessary
    >=3 monthsMinimum symptom duration required in adults
    8–17Pediatric age range eligible
    4–6 wksIntranasal steroid trial recommended
    K230742FDA pediatric indication referenced
    2RCTs cited (6‑52 wk results)

    Medical Necessity and Coverage Criteria

    Adult medical necessity

    Covered when ALL of the following are met

    Adult BDET medical necessity: 1) Symptoms of obstructive Eustachian tube dysfunction (aural fullness and pressure must be present; may include aural pressure, otalgia, hearing loss) for 3 months or longer in one or both ears that significantly affects quality of life or functional status; AND 2) Comprehensive diagnostic assessment including patient-reported questionnaires, history and physical exam, tympanometry if tympanic membrane is intact, nasal endoscopy, and comprehensive audiometry, with abnormal tympanogram (Type B or C) or abnormal tympanic membrane (retraction, effusion, perforation, or other exam abnormality); AND 3) Failure to respond to appropriate medical management of potential co-occurring conditions (e.g., allergic rhinitis, rhinosinusitis, laryngopharyngeal reflux), including a 4–6 week trial of intranasal corticosteroid spray when indicated; AND 4) Other causes of aural fullness (e.g., temporomandibular joint disorders, extrinsic obstruction of the eustachian tube, superior semicircular canal dehiscence, endolymphatic hydrops) have been ruled out; AND 5) If history of tympanostomy tube placement, symptoms improved while tubes were patent; AND 6) No patulous Eustachian tube dysfunction or other contraindication to the procedure (see policy contraindications); AND 7) Eustachian tube dysfunction has been shown to be reversible by one of the following: patient can relieve pressure with Valsalva; Valsalva produces temporary improvement of tympanogram to Type A; OR visualization of lateral TM movement/ear aeration with Valsalva; AND 8) Symptoms are continuous rather than episodic (not only barochallenge-related); AND 9) No prior BDET procedure

    Pediatric medical necessity

    Covered in pediatric patients when ALL of the following are met

    Pediatric BDET medical necessity: 1) Age 8 to 17 years; AND 2) Symptoms of obstructive Eustachian tube dysfunction with objective evidence of middle ear dysfunction (abnormal tympanometry Type B or C) OR objective middle ear disease (e.g., retraction, effusion, cholesteatoma) particularly with history of prior tympanostomy tube placement and/or adenoidectomy; AND 3) Comprehensive diagnostic assessment including history and physical exam, tympanometry if TM intact, nasopharyngoscopy, and comprehensive audiometry; AND 4) Failure to respond to appropriate medical management of alternative or co-occurring conditions that may contribute to symptoms (e.g., allergic rhinitis, rhinosinusitis, laryngopharyngeal reflux, temporomandibular joint disorder), including a trial of intranasal corticosteroid therapy for 4–6 weeks when clinically indicated; AND 5) No listed pediatric contraindications (e.g., patulous ETD, dehiscent carotid on imaging without safeguards, active infection, anatomic obstruction requiring other management, age <8, failure to confirm obstructive ETD with testing, uncontrolled allergic rhinitis or GERD, craniofacial anomalies, coagulopathy, Trisomy 21, chronic inflammatory disease or immunodeficiency).

    Initial Therapy

    Covered when ALL of the following are met

    Primary coverage requirements: 1) Patient has chronic obstructive Eustachian tube dysfunction despite medical management; AND 2) Procedure is balloon dilation of the Eustachian tube (CPT 69705 unilateral or CPT 69706 bilateral); AND 3) Medical criteria in this policy (adult or pediatric as applicable) are met.

    Evidence from randomized controlled trials and observational studies demonstrates improvement in symptoms, tympanometry, and ability to Valsalva with durable effects through 52 weeks; pediatric evidence supportive though largely observational.

    The following conditions and clinical scenarios are excluded and are considered contraindications to balloon dilation of the eustachian tube (BDET): patulous eustachian tube dysfunction; extrinsic reversible or irreversible causes such as craniofacial syndromes or other anatomic anomalies; history of radiation therapy to the nasopharynx; enlarged adenoid pads or a nasopharyngeal mass requiring alternate management; neuromuscular disorders causing ineffective ET opening; active systemic mucosal or autoimmune inflammatory disease affecting the nasopharynx/eustachian tube that is not in remission; chronic and severe atelectatic ears; and other pediatric-specific contraindications (for example, age <8 years, Trisomy 21, coagulopathy, dehiscent carotid on imaging without safeguards, active infection of the nasopharynx or middle ear, craniofacial anomalies) when present.

    This policy is provided for informational purposes and is not a guarantee of payment. Coverage, benefits, and member financial responsibility are determined by the member's subscriber agreement, member certificate, or employer agreement, which supersede this medical policy. Providers should verify member eligibility and benefits with the plan prior to treatment.

    Individuals who present with aural fullness but have a normal clinical examination and a normal tympanogram are specifically listed as not appropriate candidates for BDET and are considered not medically necessary for this procedure.

    Services that are determined to be not medically necessary under this policy are not considered covered benefits under the member's plan unless the member was informed in advance and provided written agreement to assume financial responsibility. Providers should follow contractual participation agreements and plan processes regarding non-covered services and member billing.

    Procedure Codes and Key Coding Details

    Medically necessary CPT codesCPTCovered
    69705Nasopharyngoscopy, surgical, with dilation of eustachian tube (i.e. balloon dilation); unilateral
    69706Nasopharyngoscopy, surgical, with dilation of eustachian tube (i.e. balloon dilation); bilateral
    Medically necessary CPT codesCPTCovered
    69705Nasopharyngoscopy, surgical, with dilation of eustachian tube (i.e. balloon dilation); unilateral
    69706Nasopharyngoscopy, surgical, with dilation of eustachian tube (i.e. balloon dilation); bilateral
    Symptom duration — minimum duration required in adults
    Minimum symptom duration (adults)>= 3 months of symptoms (aural fullness and pressure must be present)
    Symptom types requiredAural fullness, aural pressure; may include otalgia and hearing loss
    Symptom patternSymptoms must be continuous rather than episodic (not solely barochallenge-related)
    Improvement with tympanostomy historyIf prior tympanostomy tubes, symptoms should have improved while tubes were patent

    Prior Authorization, Documentation, and Billing Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Medicare Advantage plans and is recommended for Commercial products. Lack of prior authorization for Medicare Advantage services may result in denial of payment. Refer to the payer's Prior Authorization of Services, Treatments or Procedures policy for submission details and affected codes.

    • Applies to Balloon Dilation of the Eustachian Tube (BDET) for chronic obstructive ETD
    • Check related prior authorization policy for affected CPT codes (e.g., 69705, 69706)
    Documentation Required

    Required Diagnostic Documentation

    Providers must document a comprehensive diagnostic assessment to support medical necessity before performing BDET. Documentation should include patient-reported questionnaires, detailed history and physical examination, tympanometry if the tympanic membrane is intact, nasal endoscopy (or nasopharyngoscopy in pediatrics), and comprehensive audiometry. Objective findings such as abnormal tympanogram (Type B or C) or abnormal tympanic membrane (retraction, effusion, perforation, or other abnormalities) should be included.

    Clinical Background and Evidence Summary

    Eustachian tube dysfunction (ETD) occurs when the eustachian tube valve fails to open and/or close properly, resulting in impaired middle ear ventilation. Patients commonly report symptoms such as aural fullness, pressure, hearing loss, and otalgia, which may be persistent and affect quality of life. Left untreated, ETD can contribute to middle ear disease (for example, effusion, tympanic membrane retraction, chronic otitis media) and related complications. Balloon dilation of the eustachian tube (BDET) is a transnasal endoscopic procedure that dilates the cartilaginous portion of the tube using a balloon catheter, typically performed under general anesthesia and sometimes in conjunction with other otologic procedures, with the goal of improving tubal patency and middle ear ventilation.

    Key Definitions and Terminology

    BDET — Balloon dilation of the eustachian tube (definition)
    DefinitionTransnasal endoscopic tuboplasty in which a saline-filled balloon catheter is introduced into the cartilaginous eustachian tube and inflated to cause local dilation; pressure is maintained for 2 minutes or less before deflation and removal
    ApproachMinimally invasive transnasal endoscopic method, usually performed under general anesthesia
    Procedure contextCan be performed as a standalone procedure or with adenoidectomy, intranasal surgery, myringotomy/tympanostomy tubes, or other ENT surgeries
    DevicesIncludes FDA-classified systems such as Acclarent Aera, Xpress ENT, Nuvent, Audion ET, and Vensure balloons
    Patulous ETD — definition and distinguishing features
    Definition
    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyBalloon Dilation of the Eustachian Tube (BDET) — Clinical/Medical Policy (Draft)
    Policy CodePolicy N/A
    Change TypeMaterial updates: pediatric indication addedadult criteria clarifiedCPT codes operationalized
    Effective DateSep 1, 2026
    Last ReviewMay 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for Medicare Advantage members and document comprehensive diagnostic assessment and a 4–6 week trial of intranasal corticosteroid therapy when indicated before BDET.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaProcedure Codes and Key Coding DetailsPrior Authorization, Documentation, and Billing ActionsClinical Background and Evidence SummaryKey Definitions and Terminology
    • Include copies or summaries of questionnaires and test results (tympanometry, audiometry, endoscopy)
    • Document otoscopy findings and any prior tympanostomy tube response if applicable
    Step Therapy

    Required Conservative Therapy Trial

    Prior to BDET, providers must document a trial of conservative medical therapy and failure to respond. This includes management of contributing conditions (eg, allergic rhinitis, rhinosinusitis, laryngopharyngeal reflux, temporomandibular joint disorder) and, when clinically indicated, a 4–6 week trial of intranasal corticosteroid therapy.

    • Document duration and agents used for medical management of co-occurring conditions
    • Document intranasal steroid therapy trial (4–6 weeks) when indicated
    Documentation Required

    Requirement for Prior Medical Management

    Procedure is indicated only when obstructive ETD persists despite appropriate prior medical management of reversible or contributing conditions. Ensure records show that alternative or reversible causes (eg, extrinsic obstruction, TMJ disorder, superior semicircular canal dehiscence, endolymphatic hydrops) have been evaluated and addressed as appropriate.

    • Document evaluation and management of alternative causes and that symptoms persisted despite treatment
    • If prior tympanostomy tubes were placed, document improvement while tubes were patent (if applicable)
    Billing Rule

    Eligibility, Benefits Verification, and Member Financial Liability

    Verify member eligibility, benefits, and any financial liability before scheduling the procedure. Services determined not medically necessary or non-covered under the member's benefit plan may not be billed to the member unless the member was informed in advance and provided written agreement to accept financial responsibility.

    • Contact the provider call center or check the member's subscriber agreement for coverage details
    • Obtain written informed financial agreement if proceeding with non-covered or not-medically-necessary services
    Patulous eustachian tube dysfunction is suggested by autophony of voice, audible respirations, pulsatile tinnitus, and/or aural fullness and is a contraindication to BDET
    Clinical featuresAutophony (hearing one's own voice), perception of breathing sounds, and pulsatile tinnitus
    Policy implicationPresence of patulous ETD excludes the patient from BDET per contraindications list
    Balloon dilation of the Eustachian tube — alternate names
    Primary alternate namesBalloon Eustachian tuboplasty; BDET
    Descriptive termBalloon dilation of the Eustachian tube (tuboplasty) — dilation of the cartilaginous eustachian tube using an inflatable balloon
    AbbreviationsBDET (common abbreviation used throughout policy)